Shareholder support for its proposed merger with Bristol-Myers appears back on track.
The small-cap biotech reported encouraging news about its prostate cancer therapy.
Management's plan to acquire land to grow marijuana outdoors could result in much higher production than it's predicting.
Buying these top growth stocks could help you deliver market-beating returns.
Is one of these two cannabis companies a better buy now?
This small-cap marijuana company could be a smart, long-term stock to add to portfolios.
Shares are slipping after disappointing results, but its deep pockets could make it a cannabis company worth owning.
CannTrust's earnings disappointment is weighing on its shares, but there's reason for optimism.
Biogen's pipeline pitfall casts doubt on its strategy. Meanwhile, a shareholder revolt threatens Bristol-Myers' tie-up with Celgene.
Here's what you need to know before investing in health insurance stocks this year.
It could be the right time to add these small companies to your portfolio.
Canada's biggest cannabis company is laser-focused on the United States.
The big biotech's pivot from multiple sclerosis to Alzheimer's disease was dealt a decisive blow today.
These strategies can help biotech investors identify winners and losers.
Results from the Apple Heart Study suggest wearables like watches could someday reshape healthcare.
This cannabis company's business is booming, but it's not all good news for investors.
There are no frown lines from investors as the company is about to launch a competitor to Botox.
The high-flying marijuana company's sales soared last quarter, but its losses are mounting.
Here's why these high-income stocks can be owned in retirement portfolios.
Filing for Social Security benefits as soon as you can may be the right move if these situations apply to you.